The Company remains fully committed to its core medical device activities, continuing to advance product development, preclinical and clinical studies, and regulatory progress – including products ...
Inspire is scheduled to present at 12:45 p.m. Eastern Time. The presentation will be accessible via a live webcast here. A webcast replay of the presentation will be available for two weeks following ...
Under the terms of the agreement, ASK Pharm will obtain exclusive rights to develop, manufacture, and commercialize AN9025 in mainland China, Hong Kong and Macao (the “Licensed Territory”). Adlai ...
In December 2025, Praxis announced the successful completion of its pre-NDA meeting with the FDA, including the receipt of written feedback and an in-person meeting. The Company has aligned with the ...
NPC is an ultra-rare, relentlessly progressive, genetic disorder that leads to premature mortality. MIPLYFFA, used in conjunction with miglustat, is the only treatment shown to halt disease ...
"David brings to Indaptus significant expertise, and I look forward to working with him to evaluate the ongoing business, identify business opportunities for the Decoy platform, and seek strategic ...
ACTON, Mass., Dec. 29, 2025 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay” or the “Company”) announced that it has completed commercial-scale production of both polyclonal and ...
Format: Corporate Presentation Date: Sunday, January 11, 2026 Time: 1:20 PM PT Presenter: Laxminarayan Bhat, Ph.D., Reviva Pharmaceuticals Location: Marines’ Memorial Club, San Francisco, CA ...
Tonix Pharmaceuticals Announces Program Updates on Phase 2/3-Ready Long-Acting Monoclonal Antibody (mAb) Designed for Seasonal Prevention of Lyme Disease (TNX-4800) Exploring clinical development plan ...
Foralumab is the only fully human anti-CD3 monoclonal antibody (mAb) currently in clinical development. Immunomodulation by intranasal foralumab represents a novel avenue for the treatment of ...
The Amended Investment Policy sets out the Company’s ongoing mandate to identify and invest in early-stage and growth-stage companies developing AI-enabled technologies. The Company may also pursue ...
About the Private Placement In the Private Placement, the Company agreed to issue and sell shares of its Series Y Convertible Preferred Stock, with a stated value of $1,000 per share, together with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback